Experienced in Primary Lymphoma of the Brain

Dr. Farrokh Dehdashti

Nuclear Medicine | Radiology
Washington University
3015 N Ballas Rd, 
Saint Louis, MO 
Accepting New Patients
Experienced in Primary Lymphoma of the Brain
Washington University
3015 N Ballas Rd, 
Saint Louis, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Farrokh Dehdashti is a Nuclear Medicine specialist and a Radiologist in Saint Louis, Missouri. Dr. Dehdashti is rated as an Experienced provider by MediFind in the treatment of Primary Lymphoma of the Brain. Her top areas of expertise are Lung Nodules, Vaginal Cancer, Neurofibromatosis, and Lymphofollicular Hyperplasia. Dr. Dehdashti is currently accepting new patients.

Her clinical research consists of co-authoring 99 peer reviewed articles and participating in 20 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Nuclear Medicine
Radiology
Licenses
Diagnostic Radiology in MO
Hospital Affiliations
Barnes-Jewish West County Hospital
Barnes Jewish Hospital
Christian Hospital Northeast
Memorial Hospital Of Carbondale
Missouri Baptist Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

WASHINGTON UNIVERSITY
3015 N Ballas Rd, Saint Louis, MO 63131
Other Locations
WASHINGTON UNIVERSITY
510 S Kingshighway Blvd, Campus Box 8131, St Louis, MO 63110
WASHINGTON UNIVERSITY
11133 Dunn Rd, Saint Louis, MO 63136
WASHINGTON UNIVERSITY
510 S Kingshighway Blvd, Saint Louis, MO 63110
WASHINGTON UNIVERSITY
751 Sappington Bridge Rd, Sullivan, MO 63080
WASHINGTON UNIVERSITY
12634 Olive Blvd, Saint Louis, MO 63141
WASHINGTON UNIVERSITY
5225 Mid America Plz, Saint Louis, MO 63129
WASHINGTON UNIVERSITY
5201 Mid America Plz, Saint Louis, MO 63129

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients With Newly Diagnosed Metastatic Breast Cancer
[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients With Newly Diagnosed Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Drug
Study Drug: F-18 16 Alpha-Fluoroestradiol
Study Phase: Phase 2
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
Enrollment Status: Completed
Publish Date: December 23, 2025
Intervention Type: Device, Drug
Study Drug: Cu-64 DOTA-ECLi
Study Phase: Phase 1
Evaluation of LS301 Uptake in Tumors of Patients Undergoing Partial Mastectomy and Sentinel Lymph Node Biopsy for Breast Cancer
Evaluation of LS301 Uptake in Tumors of Patients Undergoing Partial Mastectomy and Sentinel Lymph Node Biopsy for Breast Cancer
Enrollment Status: Terminated
Publish Date: August 17, 2025
Intervention Type: Drug, Procedure, Device
Study Drug: LS301
Study Phase: Phase 1/Phase 2
Early Assessment of Response to Immune Checkpoint Blockade Therapy Using 18F-FLT PET/CT
Early Assessment of Response to Immune Checkpoint Blockade Therapy Using 18F-FLT PET/CT
Enrollment Status: Withdrawn
Publish Date: January 07, 2025
Intervention Type: Device, Drug
Study Phase: Phase 2
Phase II Non-Randomized Three Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arms 1 and 3) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): The APA Trial.
Phase II Non-Randomized Three Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arms 1 and 3) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): The APA Trial.
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug, Radiation, Biological
Study Drugs: Nab-Paclitaxel, Cisplatin, Cetuximab
Study Phase: Phase 2
Imaging CCR2 Receptors With 64Cu-DOTA-ECL1i in Head and Neck Cancer
Imaging CCR2 Receptors With 64Cu-DOTA-ECL1i in Head and Neck Cancer
Enrollment Status: Terminated
Publish Date: November 19, 2024
Intervention Type: Drug
Study Phase: Phase 1
Early Phase I Evaluation of 64Cu-LLP2A for Imaging Multiple Myeloma
Early Phase I Evaluation of 64Cu-LLP2A for Imaging Multiple Myeloma
Enrollment Status: Terminated
Publish Date: November 12, 2024
Intervention Type: Procedure, Device, Drug
Study Drug: 64Cu-LLP2A
Study Phase: Early Phase 1
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
Enrollment Status: Completed
Publish Date: July 09, 2024
Intervention Type: Drug
Study Drug: 89Zr-Df-IAB22M2C
Study Phase: Phase 2
Imaging Apoptosis for Lymphoma Treatment Response
Imaging Apoptosis for Lymphoma Treatment Response
Enrollment Status: Terminated
Publish Date: May 30, 2024
Intervention Type: Drug
Study Phase: Early Phase 1
A Confirmatory, Prospective, Open-label, Multi-centre Phase 3 Study to Evaluate Diagnostic Performance of Zirconium-labelled Girentuximab to Non-invasively Detect ccRCC by PET/CT Imaging in Patients With Indeterminate Renal Masses
A Confirmatory, Prospective, Open-label, Multi-centre Phase 3 Study to Evaluate Diagnostic Performance of Zirconium-labelled Girentuximab to Non-invasively Detect ccRCC by PET/CT Imaging in Patients With Indeterminate Renal Masses
Enrollment Status: Completed
Publish Date: May 17, 2024
Intervention Type: Diagnostic test
Study Phase: Phase 3
Positron Emission Tomography (PET) Imaging of Poly(ADP-Ribose) Polymerase (PARP) Activity in Cancer
Positron Emission Tomography (PET) Imaging of Poly(ADP-Ribose) Polymerase (PARP) Activity in Cancer
Enrollment Status: Unknown
Publish Date: December 12, 2023
Intervention Type: Drug
Study Phase: Early Phase 1
Assessment of HER2 Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using 89 Zr-Trastuzumab
Assessment of HER2 Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using 89 Zr-Trastuzumab
Enrollment Status: Completed
Publish Date: October 13, 2022
Intervention Type: Drug
Study Phase: Early Phase 1
Evaluation of Attenuation Correction Accuracy in Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)
Evaluation of Attenuation Correction Accuracy in Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)
Enrollment Status: Terminated
Publish Date: May 16, 2022
Intervention Type: Device
A Pilot Study of 89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111
A Pilot Study of 89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111
Enrollment Status: Withdrawn
Publish Date: December 23, 2021
Intervention Type: Drug
Study Phase: Phase 2
Evaluation of LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery
Evaluation of LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery
Enrollment Status: Withdrawn
Publish Date: December 09, 2021
Intervention Type: Drug, Device
Study Phase: Phase 1/Phase 2
Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography
Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography
Enrollment Status: Completed
Publish Date: January 14, 2020
Intervention Type: Drug, Device
Study Phase: Phase 2
Early Assessment of Response to Dual Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma Using 18F-FLT PET/CT and PET/MR
Early Assessment of Response to Dual Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma Using 18F-FLT PET/CT and PET/MR
Enrollment Status: Terminated
Publish Date: July 17, 2019
Intervention Type: Drug, Device
Study Phase: Phase 1
A Phase I Trial of Pazopanib Suspension Plus Cetuximab in Patients With Incurable Head and Neck Squamous Cell Carcinoma
A Phase I Trial of Pazopanib Suspension Plus Cetuximab in Patients With Incurable Head and Neck Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: April 16, 2019
Intervention Type: Drug
Study Phase: Phase 1
Reproducibility of 18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR
Reproducibility of 18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR
Enrollment Status: Completed
Publish Date: April 05, 2019
Intervention Type: Device, Radiation
Study Phase: Phase 1
Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study
Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study
Enrollment Status: Approved_for_marketing
Publish Date: January 20, 2017
Intervention Type: Drug
View 19 Less Clinical Trials

101 Total Publications

Superior Diagnostic Yield of 18F-rhPSMA-7.3 Compared With 18F-DCFPyL PET/CT for the Detection of Recurrent Prostate Cancer.
Superior Diagnostic Yield of 18F-rhPSMA-7.3 Compared With 18F-DCFPyL PET/CT for the Detection of Recurrent Prostate Cancer.
Journal: Clinical nuclear medicine
Published: September 03, 2025
Similar Doctors
Experienced in Primary Lymphoma of the Brain
Dr. Henry D. Royal
Nuclear Medicine | Radiology
Experienced in Primary Lymphoma of the Brain
Dr. Henry D. Royal
Nuclear Medicine | Radiology

Washington University

3015 N Ballas Rd, 
Saint Louis, MO 
 (0.1 miles away)
314-996-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Henry Royal is a Nuclear Medicine specialist and a Radiologist in Saint Louis, Missouri. Dr. Royal is rated as an Experienced provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Lung Nodules, Pulmonary Fibrosis, Lymphofollicular Hyperplasia, and Smoldering Multiple Myeloma. Dr. Royal is currently accepting new patients.

Experienced in Primary Lymphoma of the Brain
Dr. Randall Olsen
Radiology
Experienced in Primary Lymphoma of the Brain
Dr. Randall Olsen
Radiology

St. Luke's Hospital

232 S Woods Mill Rd, 
Chesterfield, MO 
 (3.2 miles away)
314-434-1500
Languages Spoken:
English
See accepted insurances

Randall Olsen is a Radiologist in Chesterfield, Missouri. Dr. Olsen is rated as a Distinguished provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Lung Nodules, Stroke, WT1-Related Wilms Tumor Syndromes, Vertebroplasty, and Bone Graft.

Experienced in Primary Lymphoma of the Brain
Dr. Amin Jahromi
Radiology
Experienced in Primary Lymphoma of the Brain
Dr. Amin Jahromi
Radiology

Barnes Hospital Washington University

510 S Kingshighway Blvd, 
Saint Louis, MO 
 (9.8 miles away)
314-362-2809
Languages Spoken:
English
See accepted insurances

Amin Jahromi is a Radiologist in Saint Louis, Missouri. Dr. Jahromi is rated as an Experienced provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Rosai-Dorfman Disease, Lymphofollicular Hyperplasia, Lung Nodules, Fibrous Dysplasia, and Tissue Biopsy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dehdashti's expertise for a condition
ConditionClose
        View All 23 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile